# Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

> **NCT01924195** · PHASE2 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 117 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT01924195
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-03
- **Final completion:** 2015-10
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01924195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01924195, "Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01924195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*